`APPEALS &
`INTERFERENCES
`JUN II 1992
`
`IN THE UNI'l'ED S'l.'A!rES PA'.eEN'.r AND 'J!RADEMARK OFFICE
`BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES
`
`v.
`
`PICARD ET AL
`v.
`
`FUJIKAWA RT AL
`
`INTERFERENCE 102,648
`EXAMINER-IN-CHIEF:
`MICHAEL SOFOCLEOUS
`
`:
`
`: . . . .
`: . • . •
`: . •
`
`DECLARATION--PATENTABLY DIS~INCT
`SUBJECT MM."l'ER
`
`HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS
`WASBING'l'ON, DC 20231
`.
`BOX INTERFERENCE
`
`SIR:
`
`!, MASAKI XITAHARA, do hereby declare and state that:
`
`I am a citizen and resident of Japan, and a named co(cid:173)
`1.
`inventor in u.s. Patent Application 07/233,752, involved in the
`above-captioned patent Interference.
`
`2. To demonstrate the unpredicted improvement in inhibition
`
`of cholesterol biosynthesis obtained when making specific election
`
`!
`
`•
`
`'..
`
`'.
`
`: ~- . ,_ --
`
`NCI Exhibit 2019
`Page 1 of 9
`
`
`
`2
`
`for the substituents of the subject matter of the Count of the
`
`above Interference 1 the tests described below were conducted by me 1
`
`or under my direct supervision.
`
`3.
`
`'rests were conducted to determine the impact of specific
`
`substituents on compounds of the following formula:
`
`z
`
`wherein
`
`R' =
`H
`R3 = F
`R5 = cyclopropyl (c-Pr) and z is selected from the
`group consisting of
`
`NCI Exhibit 2019
`Page 2 of 9
`
`
`
`3 , ..
`
`(carpoxylic acid),
`
`-CH(OH)-CH2-CH(OH)-CH2-COOH
`-CH(OH)-CH2-CH(OH)-CH2-COONa
`(calciwn salt),
`-CH(OH)-CH2-CH(OH)-CH2COO!Ca
`-CH(OH)-CH2-CH(OH)-CH2COOR, wherein a is C1_3 alkyl and
`
`(sodiwn salt),
`
`HO
`
`(lactone)
`
`In compounds of the above
`
`fo:rmula, where as is cyclopropyl,
`
`unpredictably enhanced inhibition of cholesterol biosynthesis, as
`
`tested both in_ vitro and in vivo (culture cell) is obtained. This
`
`unexpected improvement is maintained even when contrasted with
`
`identical compounds save for. the identity of as, wherein Rs is
`
`isopropyl or n-propyl. This is true even if the identity of R5 is
`of larger si2e, such as a c6 substituent.
`
`4.
`
`In the test described above, inhibition of cholesterol
`
`·. ~-- .. ____ ._
`
`NCI Exhibit 2019
`Page 3 of 9
`
`
`
`4
`
`biosynthesis was determined according to two tests, A and B, as set
`forth in the specification of u.s. Patent Application 07/233,752,
`involved in the above-captioned Interference. These tests are set
`
`forth and identified as tests A and B · on pages 28-30 of the
`
`speci.fication.
`
`The results of the tests are set forth in the
`
`Tables attached to this Declaration.
`
`In the tables presented, the
`
`IC50 values are given, thus indicating higher activity in compounds
`giving lower IC50 values.
`
`5.
`
`The superior activity of co.mpounds bearing a R5
`
`cyclopropyl substituent could not, on the basis of my personal
`
`knowledge and experience, be predicted on the basis of chemical
`
`structure alone. There is nothing in the art that would lead one
`
`of skill, having the approximate level of a graduate chemist with
`
`several years of experience in the field, to conclude, on the basis
`
`of structural comparison alone, that the cyclopropyl substituent at
`
`R5 would confer superior activity in the inhiPition of cholesterol
`
`biosynthesis.
`
`I hereby declare that all statements made herein of.my own
`
`knowledge are true, and all statements made on information and
`
`belief are believed true. Further, I am aware that willful false
`
`._,. ...... ,_._
`
`NCI Exhibit 2019
`Page 4 of 9
`
`
`
`5
`
`statements and the like are punishable by fine, imprisonment or
`both, 18 u.s.c. §1001, and that such willful false statements may
`jeopardize the validity of u.s. Patent Application 07/233,752, any
`patent issued thereon, as well the rights of the party Fujikawa et
`
`al in the above-captioned Interference.
`
`DATE: ____ ~Ju~n~e~1~,~1~9~9~2 ________ __
`
`;MASAKI KI
`
`. . ,. ?,_;.
`
`NCI Exhibit 2019
`Page 5 of 9
`
`
`
`•: · ...
`
`(1) Test A:
`
`Inhibition of cholesterol biosynthesis from
`
`acetate in vitro
`
`This test was carried out as described on pages 28-29
`.
`of the specification. The numerical values indicate IC50
`(nanomolar concentration i.e. mol x lo-9 ).
`(a) Sodiutn salt
`
`carbon number
`
`l
`
`2
`
`3
`
`6
`
`Rs
`
`structure
`
`(b) Calcium salt
`
`carbon number
`
`ns
`
`structure
`
`normal
`
`iso
`cyclic
`
`1
`
`-
`
`X
`
`X
`
`2
`
`-
`
`X
`
`X
`
`3
`
`-
`
`23.0(i-Pr)
`
`4.4(c-Pr)
`
`normal
`
`71.0
`
`15.0
`
`93.l(n-Pt)
`
`>1000
`
`iso
`cyclic
`
`X
`
`X
`
`X
`
`X
`
`lO,O(i-Pr)
`
`4.2(c-Pr)
`
`-
`
`51
`
`6
`
`...
`
`-
`-
`
`NCI Exhibit 2019
`Page 6 of 9
`
`
`
`;z
`
`3
`
`6
`
`24.3
`
`·39,9(n-Pr)
`
`>1000
`
`I
`
`X
`
`X
`
`-
`2.8(c-Pr)
`
`-
`96
`
`6
`
`- --
`
`2
`
`-
`
`X
`
`X
`
`3
`
`-
`
`2S.9(i-l?r)
`
`6.8(c-Pr)
`
`(c) Ethyl eJ:Stel'"
`
`ca:t:bon number
`
`Rs
`
`structure
`
`normal
`
`iso
`
`cyclic
`
`(d) Lactone
`
`carbon number
`
`Rs
`
`structure
`
`normal
`
`iso
`cyclic
`
`1
`
`-
`
`X
`
`X
`
`1
`
`-
`
`X
`
`X
`
`X: Not existing
`
`-: Not t~sted
`
`NCI Exhibit 2019
`Page 7 of 9
`
`
`
`(:2) Test B:
`
`rnhibition of cholesterol biosvnthesis in
`
`culture cells
`
`This test was carried out as described on pages 29 to
`30 of the specification. The numerical values indieate IC50
`(nanomolar concentration i.e. ~ol x l0-9).
`(a) Sodium salt
`
`carbon number
`
`Rs
`
`structure
`
`normal
`
`iso
`
`cyclic
`
`(b) Calcium salt
`
`carbon number
`
`ns
`
`structure
`
`normal
`
`iso
`cyclic
`
`l
`
`-
`
`X
`
`X
`
`1
`
`-
`
`X
`
`X
`
`2
`
`3
`
`6
`
`1050
`
`· 733(n-Pr)
`
`>10000
`
`X
`
`X
`
`lOO(i-Pr}
`
`17,S(c-Pr)
`
`-
`
`394
`
`2
`
`.
`
`X
`
`X
`
`3
`
`-
`
`l05(i-Pr)
`3S.O(c-Pr)
`
`6
`
`-
`-
`-
`
`NCI Exhibit 2019
`Page 8 of 9
`
`
`
`{c) Ethyl ester
`
`c::~rbon number
`
`as
`
`structure
`
`normal
`
`iso
`cyclic
`
`1
`
`-
`
`X
`
`X
`
`2
`
`3
`
`6
`
`797
`
`SOl(n-l?r)
`
`>10000
`
`-
`
`39.l{c-Pr)
`
`X
`
`X
`
`-
`
`4000
`
`X: Not existing
`
`-: Not tested
`
`..
`
`.... ,,
`.... . . ,
`
`• ;711.
`
`··- :--..:.. -~· .
`
`. . -.
`
`'
`
`• l
`
`-.\••' ..
`
`. . . . : .....
`. ·:·· ·: '-..!!::'·
`·.
`. .....
`·~.
`
`"';
`
`•.
`
`....
`
`~ · .
`
`,. ..
`
`NCI Exhibit 2019
`Page 9 of 9